Traditional Chinese patent medicine Zhixiong Capsule (ZXC) alleviated formed atherosclerotic plaque in rat thoracic artery and the mechanism investigation including blood-dissolved-component-based network pharmacology analysis and biochemical validation

Molecular targets of Yangyin Fuzheng Jiedu Prescription in the treatment of hepatocellular carcinoma based on network pharmacology analysis

“…Moxibustion, another TCM method, has been reported to exercise its beneficial effects through modulating the production of epidermal growth factor (EGF) and the activity of AKT serine/threonine kinase 1 (AKT1) [ 14 ]. Moreover, biochemical investigated have identified mitogen-activated protein kinase 1 (MAPK1) and jun proto-oncogene (JUN) as the key targets underlying the efficacy of the Chinese patent medicine Zhixiong Capsule [ 15 ]. Similarly, the pro-angiogenic effects and mechanism of action of Shexiang Baoxin Pill (another commonly used TCM) have been attributed to production of pro-angiogenic factor vascular endothelial growth factor A (VEGFA) [ 16 ].…”

Atheroprotective Effects and Mechanisms of Postmarketing Chinese Patent Formulas in Atherosclerosis Models: A Systematic Review

“…Of the 145 remaining articles, we further excluded 85 after screening the full text. Finally, 60 studies [ 19 – 40 ], [ 41 – 60 ], [ 61 – 78 ] were included in this analysis. A flowchart ( Figure 1 ) shows the search and study selection process.…”

“…Herein, 60 studies [ 19 – 40 ], [ 41 – 60 ], [ 61 – 78 ], encompassing 23 postmarketing Chinese patent formulas, including Danhong injection, Zhixiong capsule, Longshengzhi capsule, Tongxinluo capsule, Shexiang Baoxin pill, Danlou tablet, Angong Niuhuang pill, Longxuetongluo capsule, Longhu Rendan, Naoxintong pill/capsule, Di'ao Xinxuekang capsule, Xuezhikang, Qishenyiqi pill, ginkgo biloba tablet, Xuefu Zhuyu granule, Shexiang Tongxin dropping pill, compound Chuanxiong capsule, Yindanxinnaotong soft capsule, Dahuang Zhechong pill, Fufang Danshen dropping pill, Suxiaojiuxin pill, Xuezhitong capsule, and Guanxinshutong capsule. All the studies utilized the validated AS models and were published from 2004 to 2020.…”

“…Although none of the studies mentioned random housing, the outcome measures in the 19 studies [ 20 , 23 , 26 , 27 , 29 , 30 , 34 – 36 , 38 , 41 , 45 , 46 , 48 , 50 , 52 , 59 , 73 , 75 ] were not influenced since the feeding conditions (such as temperature, lighting, and humidity) were described, and the bias was evaluated as low risk. The incomplete outcome data were detected in 27 high-risk articles [ 19 – 21 , 23 , 26 , 32 – 36 , 39 , 45 – 47 , 50 – 53 , 55 , 56 , 60 , 61 , 68 , 74 – 77 ] without any reason or appropriate method for describing the missing data, while 18 articles [ 22 , 24 , 25 , 27 – 31 , 38 , 41 , 49 , 54 , 57 , 64 , 70 – 72 , 78 ] were unclear of the attrition bias. Although none of the studies provided any protocol, almost all had reported the expected outcome indicators, and most of them were evaluated as the low-risk bias.…”

Jian-Gan-Xiao-Zhi Decoction Ameliorates Nonalcoholic Fatty Liver Disease Through Modulating Gut Microbiota, Decreasing Gut Permeability, and Alleviating Liver Inflammation

“…For instance, researchers were able to utilize Jiang-Zhi-Ning to ameliorate high-fat diet (HFD) induced dyslipidemia through modulating the synthesis and translation of cholesterol and inhibiting oxidative stress [4]. Additionally, Zhixiong capsules have shown lipid-lowering effects on atherosclerosis model rats [5]. And Da-Huang-Ze-Xie decoction can improve dyslipidemia and hepatic steatosis in NAFLD rats through modulating gut microbiota and inhibiting the in ammatory response in liver [6].…”